This is the authors' abstract. We don't add key points for this paper.
AMD3100 (Plerixafor), a specific antagonist of CXCR4, is the most potent small molecule non-peptide inhibitor to CXCR4/CXCL12 axis. The chemokine receptor CXCR4 and its ligand CXCL12 (SDF-1) expressed in a variety of tumor cells play an important role in regulating tumor biological behavior. The tumor microenvironment (TME) is the environment around a tumor, comprising blood vessels, immune cells, fibroblasts, signaling molecules and the extracellular matrix which are involved in tumor growth, invasion, metastasis, immune escape and tumor eradication.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Huabiao Chen (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: